Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Novartis AG — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.73 (market cap $141.25M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1901.4× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Novartis AG pays a 3.31% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Novartis AG for 82 Days on average.
| KOLD | NVS | |
|---|---|---|
Market Cap | $141.25M | $268.57B |
Volume | 5,492,367 | 1,532,573 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $168.62 |
52-Week Low | $13.58 | $121.80 |
Typical Hold Time | 10 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $24.75, down 0.36% with bearish technical signals from moving averages. The stock faces pressure from record-high natural gas production and mild weather forecasts, though geopolitical tensions in the Middle East provide some support. Technical indicators show oversold conditions with RSI at 31.97, while support levels are established at $23-$25.
The outlook remains cautious with bearish technical momentum and fundamental headwinds from oversupply concerns. Near-term catalysts include geopolitical developments and winter demand, but elevated production levels and storage capacity constraints present significant downside risks for energy sector investors.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
